Author + information
- Received October 28, 2019
- Revision received February 26, 2020
- Accepted February 27, 2020
- Published online June 15, 2020.
- Raban V. Jeger, MDa,∗ (, )
- Simon Eccleshall, MDb,
- Wan Azman Wan Ahmad, MDc,
- Junbo Ge, MDd,
- Tudor C. Poerner, MDe,
- Eun-Seok Shin, MDf,
- Fernando Alfonso, MDg,
- Azeem Latib, MDh,
- Paul J. Ong, MDi,
- Tuomas T. Rissanen, MDj,
- Jorge Saucedo, MDk,
- Bruno Scheller, MDl,
- Franz X. Kleber, MDm,
- for the International DCB Consensus Group
- aUniversity Hospital Basel, University of Basel, Basel, Switzerland
- bNorfolk and Norwich University Hospital, Norwich, United Kingdom
- cUniversity Malaya Medical Centre, Kuala Lumpur, Malaysia
- dZhongshan Hospital, Fudan University, Shanghai, China
- eMarienhospital, Aachen, Germany
- fUlsan Medical Center, Ulsan Hospital, Ulsan, South Korea
- gHospital Universitario de La Princesa, IIS-IP, CIBER-CV, Madrid, Spain
- hMontefiore Medical Center, New York, New York
- iTan Tock Seng Hospital, Singapore, Singapore
- jCentral Hospital of North Karelia, Joensuu, Finland
- kMedical College of Wisconsin, Milwaukee, Wisconsin
- lUniversity Hospital Saarland, Homburg, Germany
- mPaul Gerhardt Stift, Wittenberg, Germany
- ↵∗Address for correspondence:
Dr. Raban V. Jeger, Cardiology University Hospital Basel, University of Basel, Petersgraben 4, 4031 Basel, Switzerland.
• DES still have some limitations in certain clinical and anatomic conditions.
• DCBs are a novel therapeutic strategy for coronary artery disease.
• Besides ISR, new data show possible indications for native coronary artery disease.
• Future research will focus on alternative drug coatings and other possible indications.
Although drug-eluting stents are still the default interventional treatment of coronary artery disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in certain anatomic conditions. The effect of DCBs is based on the fast and homogenous transfer of antiproliferative drugs into the vessel wall during single balloon inflation by means of a lipophilic matrix without the use of permanent implants. Although their use is established for in-stent restenosis of both bare-metal and drug-eluting stents, recent randomized clinical data demonstrate a good efficacy and safety profile in de novo small-vessel disease and high bleeding risk. In addition, there are other emerging indications (e.g., bifurcation lesions, large-vessel disease, diabetes mellitus, acute coronary syndromes). Because the interaction among the different delivery balloon designs, doses, formulations, and release kinetics of the drugs used is important, there seems to be no “class effect” of DCBs. On the basis of the amount of recently published data, the International DCB Consensus Group provides this update of previous recommendations summarizing the historical background, technical considerations such as choice of device and implantation technique, possible indications, and future perspectives.
Dr. Jeger has received research grants from B. Braun; and has received lecture honoraria from B. Braun, Nipro, and Cardionovum. Dr. Eccleshall has received research grants and lecture honoraria from B. Braun; and has received lecture honoraria from Boston Scientific. Dr. Ong has received research grants from Medtronic and Biosensors. Dr. Rissanen has received research grants and lecture honoraria from B. Braun and Boston Scientific. Dr. Saucedo is a consultant for B. Braun. Dr. Scheller is a shareholder in InnoRa; and is named as a coinventor on patent applications submitted by Charité University Hospital (Berlin, Germany). Dr. Kleber has received lecture honoraria from B. Braun. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Interventions author instructions page.
- Received October 28, 2019.
- Revision received February 26, 2020.
- Accepted February 27, 2020.
- 2020 The Authors